



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557

E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

11.08.2023

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Submission of Un-Audited Financial Results of the Company and Limited Review Report as per the provisions of Regulation 33 of SEBI (LODR) Regulations, 2015

Please find the enclosed herewith the following documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015:

1. Un-audited Financial Results of the Company for the first quarter ended 30th June, 2023.
2. A certified copy of Limited Review Report on standalone financials for the first quarter ended 30th June, 2023 given by the statutory auditors.

These are also being made available on the website of the Company at www.godavaridrugs.com.

The Board Meeting Commenced at 03:00 P.M and concluded at 04:40 PM

Please take the above in your records.

Thanking You,
For Godavari Drugs Limited

Venkatesh Achanta
Company Secretary & Compliance Officer

GODAVARI DRUGS LIMITED

CIN NO.L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023

(Rs. In Lakhs)

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	3541.88	3736.97	4255.00	15962.48
2	Other Income	45.21	15.80	6.68	65.53
3	Total Revenue from operations (1+2)	3587.09	3752.77	4261.68	16028.01
4	Expenses				
	(a) Cost of materials consumed	2644.34	3495.30	3889.63	13782.07
		162.33	-613.38	-467.12	-976.30
	(b) Changes in inventories of finished goods & work-in-progress				
	(c) Employee benefits expense	121.95	133.65	116.78	484.04
	(d) Depreciation & amortization expense	47.38	49.58	46.10	194.35
	(e) Finance Costs	110.98	102.94	74.18	392.73
	(f) Other Expenses	388.39	453.17	475.56	1680.59
	Total expenses	3475.37	3621.26	4135.13	15557.49
5	Profit before exceptional Items and tax (3-4)	111.72	131.51	126.55	470.52
6	Exceptional items	-	22.95	-	22.95
7	Profit before Tax (5-6)	111.72	154.46	126.55	493.47
8	Tax expense	-30.68	-21.33	-34.40	-114.89
9	Net Profit for the period (7-8)	81.04	133.13	92.15	378.58
10	Other Comprehensive Income				
11	Total Comprehensive Income (9+10)	81.04	133.13	92.15	378.58
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05
13	Other Equity(Reserves and Surplus)	-	2588.67	-	2588.67
14	Earnings per share (of Rs.10/- each) (not annualized)				
	(a) Basic	1.08	1.77	1.22	5.03
	(b) Diluted	1.08	1.77	1.22	5.03

Notes:

- The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 11th August 2023.
- The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.
- Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

Mohit Jaju

Mohit Jaju
CFO

DIN: 03405414



Place: Secunderabad

Date: 11.08.2023

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Godavari Drugs Limited, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to
The Board of Directors
Godavari Drugs Limited
Hyderabad.

We have reviewed the accompanying statement of unaudited standalone financial results of Godavari Drugs Limited for the Quarter ended 30th June, 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 000278S

Ayyadevara Srinivas
Proprietor
ICAI Membership No.: 028803

UDIN: 23028803BGZHJS3915

Date: 11.08.2023

Place: Hyderabad

